Compare Expensify Inc (EXFY) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs Invesco Ltd. — how do they compare? Expensify Inc trades at $2.4 (market cap $208.82M), while Invesco Ltd. trades at $29.51 (market cap $13.28B). The key difference: Invesco Ltd. is far larger — about 63.6× Expensify Inc's market cap, and Invesco Ltd. pays a 2.86% dividend while Expensify Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expensify Inc for 41 Days and Invesco Ltd. for 77 Days on average.
| EXFY | IVZ | |
|---|---|---|
Market Cap | $208.82M | $13.28B |
Volume | 456,102 | 3,698,033 |
Sector | Technology | Financials |
52-Week High | $2.72 | $33.31 |
52-Week Low | $0.75 | $22.44 |
Typical Hold Time | 41 Days | 77 Days |
Enterprise Value | $148.44M | $23.45B |
Dividend Yield | — | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.30, up 1.32% today, showing technical bullish momentum with positive moving average signals. The company reported mixed Q2 2026 results with revenue of $33.9M and improved profitability, beating EPS estimates. Recent developments include AI-native ERP integrations and European card expansion, though fundamentals show negative net margins and high P/E ratio of 258.82. Analyst consensus is bullish with a $13.75 price target, representing significant upside potential from current levels.
EXFY presents a high-risk, high-reward opportunity with strong analyst optimism contrasting with fundamental challenges. The stock's substantial discount to consensus target offers potential upside, but investors must weigh improving cash flow trends against persistent negative profitability and competitive pressures in the expense management sector.
IVZ trades at $30.09, down 1.34% on the day, with a bearish technical signal and mixed earnings history. The company reported a net loss of $281.70 million for 2025, though revenue grew to $6.38 billion. Analyst consensus is a $33.71 price target with no sell ratings, but technical indicators and recent negative profit margins highlight near-term challenges.
The outlook is cautious; while analyst support and a dividend provide some stability, persistent negative profitability and bearish technicals suggest limited upside until earnings improve. Key risks include execution on turning profits positive and market-sensitive revenue streams.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
